Regulating Together for Intellectual Disability and Autism: A Group Behavioral Therapy for for Emotion Dysregulation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-12
SponsorChildren's Mercy Hospital Kansas City

About this trial

The goal of this study is to help children with autism and a co-occurring intellectual disability and their families learn practical strategies for managing issues like irritability, aggression, and other challenging behaviors. The main objective of this study is:

To adapt current Regulating Together materials to create an outpatient group program for emotion dysregulation in autism and co-occurring intellectual disability (ASD + ID) that will improve psychosocial outcomes for youth with ASD + ID.

Eligibility criteria

Qualifiers

Males, females, or non-binary youth between 8 and 12 years of age

Confirmed diagnosis of Autism Spectrum Disorder (ASD)

Confirmed diagnosis of Intellectual Disability

Fluent in spoken English.

Disqualifiers

Initiation of new psychosocial intervention within 30 days prior to first day of treatment

Presence of physical aggression in the child directed towards a peer outside the home (i.e., non-siblings) that resulted in injury within 30 days prior to screening. Other significant disruptive, aggressive, self-injurious, or sexually inappropriate behavior felt to be dangerous or overly disruptive to the group sessions will be reviewed by the study team on an individual basis.

Presence of comorbid major neuropsychiatric illness warranting other treatment approaches

Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss

Trial design

Treatments tested in this trial

  • Regulating Together group therapy

Treatment groups

10 Participants
are divided into 1 treatment group

Sponsors and collaborators

Children's Mercy Hospital Kansas City

Lead sponsor

National Institutes of Health (NIH)

Collaborator

National Center for Advancing Translational Sciences (NCATS)

Collaborator